Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence

Objective Recently, conflicting findings have been reported on the effect of phosphodiesterase type 5 inhibitor (PDE5I) use on biochemical outcome following radical prostatectomy (RP). Thus, we investigated the impact of PDE5I treatment following RP, including therapeutic strategy, timing, duration,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of surgical oncology 2016-05, Vol.23 (5), p.1760-1767
Hauptverfasser:	Jo, Jung Ki, Kim, Kwangmo, Lee, Sang Eun, Lee, Jung Keun, Byun, Seok-Soo, Hong, Sung Kyu
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Combined Modality Therapy Follow-Up Studies Humans Male Medicine Medicine & Public Health Middle Aged Neoplasm Grading Neoplasm Recurrence, Local - prevention & control Oncology Phosphodiesterase 5 Inhibitors - therapeutic use Prognosis Proportional Hazards Models Prostatectomy Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Risk Factors Surgery Surgical Oncology Urologic Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!